serm

Tamoxifen is an orally active selective estrogen receptor modulator (SERM) that acts as an estrogen antagonist in breast cells and an agonist in bone, liver, and uterine cells. It can be used to induce gene knockout and liver injury models in mice, and also exhibits multiple biological activities, including activation of Hsp90, induction of autophagy and apoptosis, and inhibition of EBOV and MARV viral infections.

Fispemifene (HM-101) is an estrogen receptor modulator (SERM) used to treat genitourinary syndromes and vaginal atrophy.

Tamoxifen Citrate is an orally active selective estrogen receptor modulator (SERM) that blocks estrogen activity in breast cells while activating estrogen signaling in cells such as those of the bone, liver, and uterus. As an Hsp90 activator, it enhances the ATPase activity of the Hsp90 chaperone complex, induces autophagy and apoptosis, and can be used to generate gene knockout models in CreER(T2) transgenic mice as well as liver injury models.

Raloxifene hydrochloride (LY156758 hydrochloride) is a second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.

Bazedoxifene acetate (WAY-TES 424) is a novel selective estrogen receptor modulator (SERM).

Raloxifene (LY139481) is a selective estrogen receptor modulator that exhibits both estrogen agonist and antagonist activities at certain sites, with antiviral activity against viruses like Ebola, influenza, and HCV, useful for studying viral infections.

Bazedoxifene hydrochloride (TSE 424 hydrochloride) is an orally active, selective, and potent estrogen receptor modulator (SERM) that crosses the blood-brain barrier and is an inhibitor of IL-6/GP130 protein interactions with high affinity for ERα and ERβ. It has a high affinity for ERα and ERβ and can be used to study postmenopausal osteoporosis and vasodilator-related diseases.

Arzoxifene hydrochloride is a selective estrogen receptor modulator that is a potent estrogen antagonist in mammary and uterine tissue.

Disermolide is a polyketide natural product found to stabilize microtubules. Disermolide was found to be a potent inhibitor of tumor cell growth in several MDR cancer cell lines.

Sermetacin is an anti-inflammatory agent.

Mecasermin (Human IGF-I; FK 780), a recombinant form of human insulin-like growth factor I (IGF-I), is promising for investigating growth failure attributed to growth hormone (GH) insensitivity due to defects in GH receptors or the presence of GH-inhibiting antibodies [1].

Toremifene citrate is a selective estrogen receptor modulator (SERM). It is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on the mammary and uterine tissue.

Toremifene (GTx 006) is a selective estrogen-receptor modulator (SERM).

Arzoxifene (LY353381) is an orally active selective estrogen receptor modulator (SERM) with a fixed ring structure similar to raloxifene. It exhibits potent antiestrogenic effects on breast cancer and endometrium with minimal side effects and provides beneficial estrogenic effects on bone health and lipid profile.

Anti-Protein S Antibody 2 is an antibody targeting Protein S. It can be used for coagulation, thrombosis, and cardiovascular disease research.

Anti-HLA-A2 Antibody is an antibody targeting HLA-A2. It can be used for tumor immunology, inflammation, and autoimmune disease research.

4-Hydroxytamoxifen (ICI 79280) is the active metabolite of Tamoxifen, an estrogen receptor modulator (SERM) with selective and oral potency. 4-Hydroxytamoxifen has antitumor activity and may be used in breast cancer research.

Indazole-Cl is a selective ERß agonist and a selective estrogen receptor modifier (SERM).

Idoxifene (CB7432) is a selective and tissue-specific estrogen receptor modulator (SERM) that reduces collagen and malondialdehyde (MDA) levels in rat liver, exhibiting anti-fibrotic effects.

Tamoxifen-d5 is a deuterated form of Tamoxifen. Tamoxifen is an orally active selective estrogen receptor modulator (SERM) that blocks estrogen action in breast cells while activating estrogenic activity in other cells, such as those in bone, liver, and uterus. Tamoxifen is also a potent activator of Hsp90 and enhances the ATPase activity of the Hsp90 molecular chaperone.

(E)-4-Hydroxytamoxifen (Afimoxifene) is a stereoisomer and active metabolite of tamoxifen. Compared to (Z)-4-Hydroxytamoxifen, (E)-4-Hydroxytamoxifen has lower biological activity but still exhibits the characteristics of a selective estrogen receptor modulator (SERM), possessing both estrogen-like and anti-estrogen-like activities.

Estrogen receptor modulator 1 causes regression of Tamoxifen-resistant, hormone-independent xenograft tumors. Estrogen receptor modulator 1 is an orally active and selective estrogen receptor modulator (SERM) (pIC50: 0.46).

LY2066948 is a selective oral estrogen receptor modulator (SERM) with high affinity for estrogen receptors ERα and ERβ (Ki of 0.51 and 1.36 nM, respectively) and displays potent anti-estrogenic activity. It effectively blocks the increase in uterine weight induced by ethinylestradiol in immature rats. LY2066948 is utilized in the research of uterine fibroids and myomas.

Trioxifene (LY133314) is a selective estrogen receptor modulator (SERM) that competitively binds to estrogen receptor alpha (ERalpha) and exhibits antagonistic effects on ERalpha-mediated gene expression.